Ernexa Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Ernexa Therapeutics Inc. (ERNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.43 per share for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-20.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-03-11
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $2.43, a 34.68% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $3.72.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for fiscal 2019 was $2.49, a 36.15% decline from fiscal 2018.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period, weighted average grant date fair value for fiscal 2018 was $3.90.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|
| 2020-03-31 | $2.43 10-Q · filed 2020-05-20 | |
| 2019-12-31 | $2.49 10-K · filed 2021-03-11 | |
| 2019-03-31 | $3.72 10-Q · filed 2020-05-20 | |
| 2018-12-31 | $3.90 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |